Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

ERAS-4001

Small molecule · Inhibitor of KRAS · developed by Erasca

Phase 1 Most advanced trial
ERAS Developer
1 Registered trials

What is ERAS-4001?

ERAS-4001 is an orally bioavailable pan-KRAS inhibitor that binds KRAS wild-type and various KRAS mutant forms, inhibiting KRAS-dependent signaling. It is being studied in metastatic solid tumors, alone and in combination with pembrolizumab or panitumumab.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Targets
KRAS
Mechanism
Inhibitor of KRAS
Pathways
KRAS-dependent signaling, cell growth and survival signaling
Therapy area
Oncology
Developer
Erasca, Inc. (ERAS)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07021898 Phase 1 Metastatic Solid Tumors Recruiting ERAS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Metastatic Solid Tumors

Other drugs acting on KRAS

More from Erasca

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the ERAS page.

Follow ERAS, the company behind ERAS-4001

See ERAS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ERAS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.